共 50 条
- [31] STUDIES OF ANTIBODY-DEPENDENT ENHANCEMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-1 INFECTION MEDIATED BY FC-RECEPTORS USING SERA FROM RECIPIENTS OF A RECOMBINANT GP160 EXPERIMENTAL HIV-1 VACCINEJOURNAL OF INFECTIOUS DISEASES, 1992, 165 (03): : 545 - 548HAUBRICH, RHTAKEDA, AKOFF, WSMITH, GENNIS, FA
- [32] NEUTRALIZING ANTIBODIES AGAINST HIV-1 BRU AND SF2 ISOLATES GENERATED IN MICE IMMUNIZED WITH RECOMBINANT VACCINIA VIRUS EXPRESSING HIV-1 (BRU) ENVELOPE GLYCOPROTEINS AND BOOSTED WITH HOMOLOGOUS GP160AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (07) : 615 - 620HU, SLKLANIECKI, JDYKERS, TSRIDHAR, PTRAVIS, BM
- [33] Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapyJOURNAL OF VIROLOGY, 2002, 76 (05) : 2206 - 2216Jin, XRamanathan, MBarsoum, SDeschenes, GRBa, LBinley, JSchiller, DBauer, DEChen, DCHurley, AGebuhrer, LEl Habib, RCaudrelier, PKlein, MZhang, LQHo, DDMarkowitz, M
- [34] Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160ΔV1V2 is strongly immunogenicVIROLOGY, 2009, 388 (01) : 191 - 203Guerbois, MathildeMoris, ArnaudCombredet, ChantalNajburg, ValerieRuffie, ClaudeFevrier, MicheleCayet, NadegeBrandler, SamanthaSchwartz, OlivierTangy, Frederic
- [35] Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlledRETROVIROLOGY, 2009, 6Salmon-Ceron, D.Durier, C.Desaint, C.CuzinSurenaud, M.Henin, Y.Lelievre, J.Bonnet, B.Pialoux, G.Poizot-Martin, I.Ben Hamouda, N.Jackson, A.Flys, C.Guerin, C.Aboulker, J.Choppin, J.Launay, O.
- [36] Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trialVACCINE, 2021, 39 (29) : 3879 - 3891Chua, Joel V.Davis, CharlesHusson, Jennifer S.Nelson, AmyPrado, IliaFlinko, RobinLam, Ka Wing J.Mutumbi, LydiahMayer, Bryan T.Dong, DanFulp, WilliamMahoney, CeliaGerber, MonicaGottardo, RaphaelGilliam, Bruce L.Greene, KelliGao, HongmeiYates, NicoleFerrari, GuidoTomaras, GeorgiaMontefiori, DavidSchwartz, Jennifer A.Fouts, TimothyDeVico, Anthony L.Lewis, George K.Gallo, Robert C.Sajadi, Mohammad M.
- [37] Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trialAIDS, 2008, 22 (13) : 1601 - 1609Walson, Judd L.Otieno, Phelgona A.Mbuchi, MargaretRichardson, Barbra A.Lohman-Payne, BarbaraMacharia, Steve WanyeeOverbaugh, JulieBerkley, JamesSanders, Eduard J.Chung, Michael H.John-Stewart, Grace C.
- [38] ASCENT: Phase 2a, randomized, double-blind, placebo controlled study evaluating safety and immunogenicity of two HIV-1 prophylactic vaccine regimens comprising Ad26. Mos4. HIV and either clade C gp140 or bivalent gp140JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 98 - 98Stieh, D. J.Tomaka, F.Comeaux, C. A.Nijs, S.Callewaert, K.Hendriks, J.Euler, Z.Tomaras, G. D.Alter, G.Kublin, J.Corey, L.McElrath, J.Swann, E.Robb, M.Michael, N.Marovich, M.Pau, M. G.Barouch, D. H.Schuitemaker, H.
- [39] Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trialECLINICALMEDICINE, 2020, 27Abarca, KatiaRey-Jurado, EmmaMunoz-Durango, NataliaVazquez, YaneisiSoto, Jorge A.Galvez, Nicolas M. S.Valdes-Ferrada, JavierIturriaga, CarolinaUrzua, MarcelaBorzutzky, ArturoCerda, JaimeVillarroel, LuisMadrid, VictoriaGonzalez, Pablo A.Gonzalez-Aramundiz, Jose, VBueno, Susan M.Kalergis, Alexis M.
- [40] Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, ThailandJOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12): : 1661 - 1671Pitisuttithum, PunneeGilbert, PeterGurwith, MarcHeyward, WilliamMartin, Michaelvan Griensven, FritzHu, DaleTappero, Jordan W.Choopanya, Kachit